Disease progression strikingly differs in research and real-world Parkinson's populations 1

- 2
- Brett K. Beaulieu-Jones^{1,2,3,4,5}, Francesca Frau⁶, Sylvie Bozzi⁷, Karen J. Chandross⁸, M Judith Peterschmitt⁹, Caroline Cohen¹⁰, Catherine Coulovrat¹¹, Dinesh Kumar¹¹, Mark J. Kruger⁹, Scott L. Lipnick¹, Lane Fitzsimmons¹, Isaac S. Kohane¹, Clemens R. Scherzer^{2,3,5} 3
- 4
- 5
- 6
- 7 1 Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
- 8 2 APDA Center for Advanced Parkinson Research of Harvard Medical School and Brigham and
- 9 Women's Hospital, Boston, MA 02115, USA.
- 10 3 Precision Neurology Program of Brigham & Women's Hospital, Harvard Medical School,
- 11 Boston, MA 02115, USA.
- 12 4 Department of Medicine, University of Chicago, Chicago, IL 60615 USA.
- 13 5 Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase
- 14 MD, 20815
- 15 6 Sanofi R&D, Data and Data Science, Frankfurt, Germany.
- 16 7 Sanofi Health Economics and Value Assessment, Sanofi, Paris, France.
- 17 8 Sanofi R&D, Bridgewater, NJ, United States.
- 9 Sanofi Genzyme, Clinical Development Neurology, Cambridge, MA, United States. 18
- 19 10 Sanofi R&D, Paris, France
- 20 11 Sanofi Translational Sciences, Framingham, 01701 USA
- 21

22 Abstract

23

Characterization of Parkinson's disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Efforts to curate research populations, the increasing availability of real-world data and recent advances in natural language processing, particularly large language models, allow for a more granular comparison of populations and the

- 28 methods of data collection describing these populations than previously possible.
- This study includes two research populations and two real-world data derived (RWD) populations. The research populations are the Harvard Biomarkers Study (HBS, N = 935), a
- 31 longitudinal biomarkers cohort study with in-person structured study visits; and Fox Insights (N
- 32 = 36,660), an online self-survey-based research study of the Michael J. Fox Foundation. Real-
- 33 world cohorts are the Optum Integrated Claims-electronic health records (N = 157,475),
- 34 representing wide-scale linked medical and claims data and de-identified data from Mass
- 35 General Brigham (MGB, N = 22,949), an academic hospital system. Structured, de-identified
- 36 electronic health records data at MGB are supplemented using natural language processing with
- a large language model to extract measurements of PD progression. This extraction process is
- 38 manually validated for accuracy.
- 39 Motor and cognitive progression scores change more rapidly in MGB than HBS (median
- 40 survival until H&Y 3: 5.6 years vs. >10, p<0.001; mini-mental state exam median decline 0.28
- 41 vs. 0.11, p<0.001; and clinically recognized cognitive decline, p=0.001). In the real-world
- populations, patients are diagnosed more than eleven years later (RWD mean of 72.2 vs. research
 mean of 60.4, p<0.001). After diagnosis, in real-world cohorts, treatment with PD medications is
 initiated 2.3 years later on average (95% CI: [2.1-2.4]; p<0.001).
- This study provides a detailed characterization of Parkinson's progression in diverse
 populations. It delineates systemic divergences in the patient populations enrolled in research
 settings vs. patients in the real world. These divergences are likely due to a combination of
- 48 selection bias and real population differences, but exact attribution of the causes is challenging
- 49 using existing data. This study emphasizes a need to utilize multiple data sources and to
- 50 diligently consider potential biases when planning, choosing data sources, and performing
- 51 downstream tasks and analyses.

52 Introduction

53

54 Despite substantial investment and increased biological understanding, disease-modifying 55 therapies for Parkinson's disease (PD) have not yet proven successful.¹ Therapies recently considered to be promising in preclinical and early clinical trials have failed at later stages.² 56 57 There are numerous challenges to developing disease-modifying therapies for PD. Perhaps most 58 importantly, we lack a complete understanding of the molecular processes driving disease pathogenesis.^{3–5} A wide range of PD onset ages and differing patterns of disease progression 59 suggest heterogeneity.⁶⁻⁸ Recently, genome-wide survival studies have identified six loci ---60 61 GBA, APOE, RIMS2, TMEM108, WWOX, and the mitochondrial super macro haplogroup J,T,U --- associated with genetic heterogeneity in the progression from PD to Lewy body dementia.⁹⁻¹³ 62 63 This is important because homogeneous patient populations and an accurate measurement of 64 disease progression would greatly facilitate clinical trial design. More homogenous 65 subpopulations may make biomarker associations more powerful, clarify the genetic basis for disease, and lead to more successful therapeutic development.^{12,14} 66

67 Characterization of Parkinson's disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Most prior work examining PD 68 progression focused on research data from major academic centers,¹⁵ but this may not accurately 69 reflect the population at large.^{8,16} It is important to determine whether analyses performed in one 70 71 particular data modality will lead to generalizable results. Large scale adoption of electronic 72 health records and recent advances in natural language processing (NLP) could be used to 73 address this knowledge gap. Individual health systems (e.g., Mass General Brigham, MGB)¹⁷ and large national managed care providers (e.g., UnitedHealth Group, Optum)¹⁸ have developed 74 75 robust databases in the form of electronic health records (EHRs) through routine care. Even after 76 filtering to enrich for newly diagnosed PD patients-those who had at least two years of data 77 prior to diagnosis-Optum includes 157,475 patients with at least two PD diagnoses and MGB 78 has a further 13,257 patients. It is important to note that while large, inclusion in these datasets is 79 driven by access to care (e.g., insurance, socioeconomic factors) at MGB or within UnitedHealth 80 Group. In addition to these new sources of real-world data (RWD), natural language processing 81 and especially large language models have recently achieved improved performance on 82 benchmark evaluations by substantial margins. In this work, we leverage these improved models 83 to supplement structured EHR data at MGB by extracting phenotypic information, particularly clinical scores from clinical notes.¹⁹⁻²³ To ensure the model's extraction process is accurate, it is 84 85 straightforward to perform manual chart review on a sample set of notes.

In this study we provide a comparison between two research studies and two RWD sources. While the research cohorts were actively recruited, the RWD are "passively" collected because they are derived from typical clinical care and not explicitly for research purposes. We characterized PD progression to better understand "typical" progression across the four research and real-world data sources. We evaluated the strengths and weaknesses of these data sources to characterize PD progression and their potential to enable more precise endophenotyping.

In performing this evaluation, we acknowledge and emphasize substantial potential
sources of bias related to the way the different datasets were collected. For example, in the Fox
Insight study, patients are recruited through online advertising, and they provide their data
through an online portal. Within HBS, patients must have a Mini-Mental State Examination
(MMSE) score consistent with the ability to provide informed consent or their next of kin must
be present to provide consent. While ethically critical, criteria like this may systematically

98 exclude certain participants, those that are older may be less likely to have and use the internet

99 on their own, may have lower MMSE scores and be less likely to be in close contact or

100 proximity with their next of kin. On the other hand, RWD are available only in the context of an

- individual's interactions with healthcare and can be biased by access to healthcare and other
- 102 socioeconomic factors. Additionally, analyzing RWD requires specifying rules for inclusion,
- 103 clinical event, and outcome definitions. Reasonable changes to these rules have the potential to 104 significantly change results.²⁴
- 105 This study examines the differences of PD progression between these data modalities 106 with the intent of providing guidance for future studies. By better understanding potential biases 107 in data, future study of potential disease-modifying therapies can be designed to minimize these 108 biases. This can be done by choosing the appropriate data for the question at hand and including

109 multiple data modalities to help determine whether effects are artifacts of the data source or

110 accurate measures of progression. This has the potential to aid future studies by providing

111 guidance of when changes in progression are significant, the determination of appropriate

112 clinical endpoints, and baselines for the identification of patient subpopulations of interest.

113

114 **Results**

115 The study took place across four different datasets, two research populations: the 1) 116 Harvard Biomarkers Study (HBS), and the 2) Fox Insight longitudinal health study (Fox Insight);

and two real-world populations: 3) Mass General Brigham electronic medical records (MGB),

and two rear-world populations. 5) Mass General Brigham electronic medical fectors (MOB),

and 4) Optum Claims-EHR dataset (Optum). This study was approved by the Mass General

Brigham IRB. HBS, Fox Insight and Optum are de-identified and MGB electronic medical

records were accessed through the Research Patient Data Registry. All work was retrospective

review without additional contact or intervention in accordance with the IRB. No linking

122 between datasets was performed.

123

124 Table 1. Cohort Characteristics for HBS, MGB, Optum, and Fox Insights cohorts

	HBS	Fox Insight	MGB	Optum Claims-
T (1 D 1 (025	26.660	22.040	EHK
Total Population	935	36,660	22,949	157,475#
with PD				
Population with data	935	36,660	13,257	157,475#
since initial PD				
diagnosis				
Percentage of	67.0%	55.8%	57.8%	56.7%
population with data				
from initial PD				
diagnosis who are				
Male				
Mean Age at	62.5 [56.0 - 70.0]	60.3 [53.6-61.3]	72.9 [66.5 - 81.2]	72.1 [66.0-80.0]
diagnosis (years)				
[25% and 75%]				
Mean Years from	3.7 [0.0 – 5.0]	3.5 [1.2-7.5]	NA	NA
Diagnosis to Study				
Enrollment [25%,				
75%]				
Mean Initial H&Y	2.1 [2, 2, 2.5]	NA	2.3 [2, 2, 3]	NA
Stage if recorded	n=853		n=1,071	
within 1 year of				
diagnosis (MGB) or				

at enrollment (HBS)				
[25%, 50%, 75%]				
Mean Length of	6.2 [2.0-9.0]	1 [0-1.0]*	3.8 [0.7 – 5.6]	3.1 [0.6-4.9] ^
Follow-up from				
disease diagnosis				
(years) [25%, 75%				
percentile]				

125 * Years enrolled within Fox Insight. Due to survey nature of data source, historical data are available for certain

126 information.

127 # Subjects at MGB and Optum were only included if they had at least two years of data coverage prior to initial PD 128 diagnosis. This quiescence period was designed to filter for de novo diagnoses.

- 129 The research populations (HBS and Fox Insight) had lower age of PD diagnosis than the 130 real-world populations (mean 60.4 vs. 72.2, p < 0.001, Table 1). Fox Insight had a shorter length 131 of follow-up after enrollment, limited by the fact that it is a new resource. HBS demonstrated the 132 potential for research data sources to offer significant longitudinal data that is thus far difficult to 133 find in RWD (mean follow-up time of 6.1 years vs. 3.2 years, p < 0.001). Finally, because the 134 research cohorts were actively enrolled, there is the potential to collect additional history, for 135 example the timing of an initial PD diagnosis is available for all participants of HBS and Fox 136 Insight, but it must be extracted with rules from the RWD sources.
- 137 Within HBS, clinical rating scales are actively collected, recorded as structured data and 138 are available in most patients (Table 1, 853/935: 91.2%). In MGB they are passively collected 139 and were extracted from the clinical notes for a small proportion of patients (1,071/13,257: 8.1%), 140 extraction process described in methods). Clinical scores are not available in Optum. To evaluate 141 the effects of potential interventions, it is important to understand the typical progression of PD. 142 Clinical rating scales, including H&Y, MMSE, UPDRS and MoCA represent common clinical 143 study endpoints for Parkinson's progression. We compared progression of these measures 144 between HBS, an actively assessed research cohort and MGB, a real-world cohort where data are 145 available only if they are collected as a part of routine clinical care (i.e., passive data collection). 146 We compared the cohorts by stratifying patients based on their time from initial diagnosis and 147 compared clinical scores (Figure 1). We observe several key results: first, scores within HBS 148 show slower movement than MGB in general than HBS. Outside of the UPDRS total score for 149 MGB, the scores do not change substantially during the length of time of typical clinical trials 150 (1-5 years). MMSE was significantly higher throughout the first five years within HBS (p<0.001, 151 Figure 1C). Finally, the biggest change in progression is observed in the UPDRS total score, with 152 the median score at MGB doubling by year 6.
- 153





HBS). MGB were only available for up to ten years due to patient size drop-off. A.) Hoehn & 156 Yahr Stage (MGB & HBS), B.) UPDRS Total Score (MGB & HBS), C.) MMSE Score (MGB &

- 157 158 HBS),
- 159
- 160 Survival against key clinical events including levodopa initiation, reaching H&Y Stage 3,
- 161 and discharge to long term care, first falls, or fractures after PD diagnosis, diagnoses of
- depression, and diagnoses of dyskinesias were evaluated in each of the data sources. We 162
- 163 observed significantly earlier start of PD medications in the research populations compare to the

real-world populations (p < 0.001). This was particularly pronounced in the Fox Insights data (Figure 2A). A potential explanation for this outlier result in Fox Insights could be that it entirely relies on patient self-reports. Interestingly, patients in the EMR data (MGB) were overall started on PD medications later than the research cohorts, however, initiation of levodopa therapy specifically overlapped with the research cohorts (Figure 2B). This may indicate that newer nonlevodopa PD medications may be more aggressively prescribed in the patients participating in the research cohorts. Patients in RWD reached a H&Y score of 3 or more (Figure 2C, p < 0.001)

171 or matched the definition for cognitive decline (Figure 2D, Optum vs. HBS, p < 0.001, MGB vs.

172 HBS, p=0.001) sooner after diagnosis than those in the research settings.

173 Additionally, we examined the association between disease duration (e.g., years since PD 174 diagnosis) and the clinical rating scale score conditioning on the age of diagnosis, sex, and 175 number of years of education (years of education is available in HBS only). For UPDRS, after 176 adjusting for covariates, the intercept was 18.93 in MGB and 28.25 in HBS. At the intercept, the 177 MGB slope was more than double that of HBS (3.87 vs. 1.54 within HBS, p < 0.001). Prior 178 studies have estimated a 3 to 14 total UPDRS change per year, making the observed values in HBS lower than previously reported.²⁵ Slopes for H&Y were not observed to be significantly 179 180 different between MGB and HBS (Supplemental Table 4). While H&Y ranges from 1-5, few 181 patients were observed on either extreme, indicating that this measure may not be sensitive 182 enough to observe differences in the follow-up period. Finally, after adjusting for covariates, 183 significant differences were observed between MMSE scores both at the time of diagnosis (HBS: 184 28.7, MGB: 25.8) and in terms of progression (HBS: 0.11 annual decline, MGB: 0.28 annual 185 decline). Thus, both survival models and the linear regression model (Supplemental Table 4) are 186 consistent with more rapid motor and cognitive decline in real-world vs. research population 187 data. The change in H&Y is in line with what is previously reported in the literature 188 (Supplemental Table 5).

189 Additionally, we broke down the percentage of patients who started therapy with 190 levodopa by their H&Y stage (Supplemental Table 6). By H&Y stage 2.5 >80% of patients had 191 initiated levodopa and we did not see any further increase. This is consistent with clinical 192 guidelines indicating levodopa should be started in patients over 65 upon mild symptoms and for all symptoms as moderate or severe symptoms present.²⁶ This plateau of ~80-85% levodopa 193 194 initiation during the study follow-up period indicates an upper limit on the utility of the surrogate 195 measure of levodopa initiation to track PD progression. Levodopa provides a benchmark for the 196 treatment of many PD symptoms which can be used as a tool to compare experimental disease 197 modifying therapies or to plan future clinical trials.



198

199 **Figure 2.** Survival against key clinical events. **A.**) Proportion of patients not started on

- 200 Levodopa, B.) Proportion of patients not started on PD medications, C.) Proportion of patients
- with $HY \leq 3$ (smaller or equal) (MGB, HBS), **D.**) Proportion of patients who have not
- 202 experienced Cognitive Decline Proxy (MGB, HBS, Optum)

We then examined the incidence of complications with major effects on patients' quality 203 of life, that is, fractures and falls; and depression.^{27,28} We observed a substantially higher and 204 earlier incidence of fractures and falls as well as depression diagnoses in Optum compared to 205 206 MGB data (p < 0.001, Figure 3A, 3B). The interpretation of this divergence is complex. The 207 difference could be due to distinct care utilization; primary vs. tertiary point of care; general 208 neurologist vs. movement disorders specialty care; or other systemic differences in the patient 209 populations such as socio-economical divergence. This result indicates the need to examine 210 results from RWD in the context of healthcare delivery.

211



212

Figure 3. Survival against indirect adverse events in RWD. A.), Fractures & Falls (MGB,
Optum), B.) Depression (MGB, Optum).

215

216 **Discussion**

217 This work examines PD progression across four different datasets, two research 218 populations and two real-world data populations. It demonstrates the ability to utilize large 219 language models to extract clinical rating scores from clinical notes as part of routine care and to 220 compare these scores to a research-level, longitudinal clinical observational study. This work 221 shows progression patterns in clinical rating scales and fit models to estimate "typical" 222 progression across the irregularly spaced events common in healthcare. A key purpose of this 223 study is to illustrate that while we observe these differences, it is difficult to attribute these 224 differences to specific sources. They are likely to be driven at least in part by biases specific to 225 each data source and collection mechanism, the populations within each data set as well as 226 clinical care provided within each data source. By preforming these analyses across four 227 different data modalities, this work aims to provide a diverse set of measures accessible to 228 researchers with access to different data sources. We hope that it can help researchers choose the

appropriate data modality, or ideally multiple modalities, for their research question and toapproach their analyses paying careful attention to sources of bias.

The study shows systematic differences and potential directional biases between research and real-world data sets (Figure 4). Patients in research populations are diagnosed much earlier, are started earlier on levodopa and other PD medications, and have slower changes in clinical scales of motor and cognitive progression. RWD-based populations are diagnosed at an older age, start medications later than research cohorts and have faster changes in clinical scales and events geared at measuring motor and cognitive decline. RWD-based populations offer

- substantially larger sample sizes, do not require active recruitment, and may be available
- 238 immediately for past populations. Most importantly, RWD-based populations may be more
- representative of routine clinical care and thus may be more reflective of the general population.

240



241

Figure 4 Comparison of PD phenotypic resources, research populations vs. real-world data and local vs. remote demonstrating the pros and cons of each data modality for PD research.

244

245 Which variables may underlie the divergent progression features in the real vs. the 246 research world? We hypothesize that several factors may play a role:

1.) The way cohorts were recruited (e.g., actively recruited research datasets or passively
generated real world data extracted from routine clinical care). This may lead to recruitment bias
for younger and more educated patients into research studies.^{16,29} We previously observed

"proxy" diagnoses where a non-specialist might diagnose a patient with a less specific gait, 250 tremor, or cognitive disorder as justification for a referral to a movement disorders specialist.³⁰ 251 252 One potential explanation for this pattern could be a hesitation to make a diagnosis as severe as 253 PD without being completely confident. Populations enriched for Mendelian forms of PD have 254 been observed to have an earlier disease onset and could be over-represented among the research 255 populations. Their earlier diagnosis of PD may be the result of greater access to specialists 256 resulting in a faster transition from a "proxy" diagnosis to PD. Due to critical ethical 257 requirements, HBS requires cognitive competency or a next of kin to provide informed consent. This requirement may exclude clinical subtypes of PD more likely to have substantial cognitive 258 decline before they are able to be recruited and enrolled.³¹ In contrast, patients with later 259 diagnosis and patients with the postural instability-gait difficult (PIGD) form of PD have both 260 been observed to have faster UPDRS part II³² as well as general cognitive³³. There is a 261 relationship between PIGD and disease duration^{34,35}, so accurate assessment of disease onset is 262 263 critical for future studies of subtypes. This study emphasizes the challenges in differentiating 264 potential phenotypic subtypes from confounding factors such as disease duration.

265 2.) The specialization of care, particularly in terms of what is deemed relevant for
266 treating (MGB) or studying PD (HBS) may dictate which data are collected and how they are
267 collected in comparison to networks that should have comprehensive coverage of all care
268 (Optum). This discrepancy may be a large component of the differences in survival against
269 depression as well as falls and fractures.

270 3.) The source of the data (e.g., provider vs. patient provided) may have led to 271 exaggerated differences between Fox Insight and the other data sources. This was especially 272 relevant regarding PD-therapeutic initiation. In contrast to data from each of the other sources, 273 most patients within Fox Insight believed they immediately started a PD-therapeutic. The 274 different data sources also dictated which analyses were possible, this was especially seen in 275 longitudinal analyses reliant on follow-up periods. Fox Insight represents a new data source and 276 therefore the length of follow up was limited. However, HBS demonstrates the potential for 277 research data sources to offer significant longitudinal data that is difficult to find in RWD (mean 278 follow-up time of 6.1 years vs. 3.2 years, p < 0.001). This comparison between data modalities 279 may be related and may help to quantify potential "hawthorne effects", where greater interaction between participant and physician can lead to differing outcomes.^{36,37} 280

281 As RWD becomes increasingly available, it is critical to understand the strengths and 282 weaknesses of different sources of data and analytical approaches. This study identified 283 important limitations for each of the datasets. HBS has strengths in terms of the quality of 284 targeted data (e.g., environmental exposures, clinical rating scales, genetics) but given its nature 285 as longitudinal biomarkers study with structured study visits, it is comparatively small in 286 participant numbers. As it is based at a single site in Boston, it also may not be representative of 287 the diversity of PD across the nation. MGB shares this issue of representation but has 288 approximately 25 times as many participants as HBS (22,949 vs. 935) and includes data 289 extracted from typical clinical care records for PD (i.e., real-world data). Patients at MGB and 290 HBS are predominantly of European descent, while ethnicity data were not available in the 291 licensed Optum dataset. This meant, that despite being large data sources, we were not able to 292 subset people with PD according to race or ethnicity in search of different progression patterns. 293 We do however, suspect that there are substantial biases related to access to care within both 294 MGB and Optum. MGB is a highly ranked academic health system and those with means such as 295 insurance, ability to travel, and the support of caregivers who can afford time away to help may

be more likely to seek out care at MGB as opposed to whichever provider is closest. Similarly, 296 297 while geographically broad, Optum is still highly enriched for private insurance and the Midwest 298 region. These factors are not easy for single organizations, even organizations with as many 299 resources as these to mitigate. Less biased data may require system-wide intervention or efforts 300 such as government supported registries universal access to care. Studying neurodegenerative 301 conditions that frequently emerge around the age of retirement is especially challenging as 302 people frequently switch insurers or even move to new locations for retirement. In both cases, 303 neither the claims data nor provider data alone can be relied upon. The population that has 304 continuous data is likely to be biased by those that retire later and among other potential biases 305 may be healthier or have increased socioeconomic needs to continue working.

306 Efforts such as Fox Insight have the potential to alleviate some of these challenges by 307 recruiting for a large, diverse, patient population but this will require intentional effort. 308 Importantly, Fox Insight also collects genetic data allowing for more accurate determination of 309 ethnicity. Otherwise, limitations of EMR data sources like MGB include the fact that genetics are 310 only available on a small subset of patients. Consequently, even where ethnicity data are 311 available, analyses are often dependent on patient reported ethnicity rather than genetic ancestry. 312 However, even this effort is subject to substantial bias since patients must interact with the study 313 online, meaning the patient or someone close to the patient needs to have internet access. Adding 314 to the access question, Fox Insight leverages online advertising and the populations who spend 315 more time online may be more likely to discover Fox Insight.

316 Additionally, clinical scores are not typically captured in structured EHR data, there is no 317 guarantee of completeness of care, there are censoring challenges, and these scores are based on subjective assessments. Future assessments using biomarkers (e.g., RT-OuIC³⁸) may enable the 318 319 measurement of progression in settings without experts trained in different clinical scales and 320 may provide faster and more objective measurement of progression even when experts are 321 available. Optum, as a combination of EMR and administrative claims data, improves upon the 322 challenges of completeness of care data but has less per-patient granularity than identified EMR 323 data. For example, in some cases it may be possible to extract clinical rating scores, but because 324 end users do not have access to Optum's proprietary natural language processing extraction code 325 or the raw notes the values are extracted from, it's not possible for an end user to validate the 326 extraction. Within MGB it was possible to compare the extracted values to manual chart review-327 extracted values to validate that the NLP extraction process worked accurately. We are actively 328 working to generalize this approach to share it as open-source software after evaluating in 329 additional settings and cohorts. Without being able to validate the extraction process in Optum, 330 it's difficult to assess whether the extracted values can be used for downstream analyses with 331 sufficient confidence. For this reason, we excluded the clinical rating scales available within 332 Optum from our analyses. Despite these challenges, Optum includes nearly eight times the 333 number of patients as a single site EMR like MGB and is likely more representative of national 334 demographics of PD. We believe that future studies would benefit greatly from comparing both 335 between RWD-sources as well as between the cohort of interest and background control 336 populations. A limitation of this study was the lack of access to control populations in resources 337 like Optum due to data licensing.

Finally, the Fox Insight study, is relatively new and therefore has limited follow-up time.
Fox insight's web-based recruitment and information collection model have demonstrated
promise, rapidly recruiting tens of thousands of PD patients. Because it is survey-based, there is

341 likely to be heterogeneity in response quality (e.g., therapeutic initiation), and unlike the other

- 342 data sources, it is patient-provided. Data are not entered by physicians and clinical research
- 343 affiliates. Additionally, Fox Insight, currently collects a history of the presence of clinical events
- 344 but does not currently collect the date of occurrence. This may be difficult for subjects to
- 345 remember but would be useful in characterizing progression (i.e., survival analyses require dates
- of clinical events). We hope that this work can provide guidance to future efforts of this
- 347 emerging resource as well as aid in the design of future studies.
- 348 Due to the heterogeneity of PD, a better understanding of the "ground truth" of
- 349 progression is critical for the development of disease-modifying therapeutics. This understanding
- 350 may enable the identification of subpopulations for target discovery and improve the design of
- clinical trials (e.g., selection of more appropriate endpoints). Finally, without a better
- 352 understanding of current progression, it is difficult to value therapeutics which may slow
- 353 progression according to patient quality of life and healthcare cost savings.
- 354 355

356 Methods

357 Data Sources and Study Population

358 Harvard Biomarkers Study

The Harvard Biomarkers Study (HBS) is a longitudinal case-control registry which aims to accelerate the development of molecular diagnostics which track or predict progression of

361 early-stage PD.^{10,39–41} The study includes participants with PD, mild cognitive impairment,

362 Alzheimer's disease in addition to healthy controls. Participants are recruited from throughout

- 363 Mass General Brigham and enroll for at least three years though the Memory and Movement
- 364 Disorders Units at Brigham & Women's Hospital and Massachusetts General Hospital. Full study
- information is available in study publications^{9,40,42} and online
- 366 (https://www.bwhparkinsoncenter.org/).

PD cases are defined according to the UK PD Society Brain Bank Criteria¹ or a
 movement disorders specialists' assessment. Cases were required to have Mini-Mental State

369 Examination (MMSE) scores >21 or the next of kin present to provide informed consent. PD

 $370 \qquad \text{cases were excluded for presence of blood disorders, hematocrit levels < 30\%, and active ulcers}$

371 or colitis. Clinical disease severity is measured in the "operational on state" according to

clinician expert judgement, but patients were not necessarily at the peak response ("true onstate").

At the time of this analysis, the study included a total of 1,914 participants including 935 with PD and 979 healthy controls. The biobank includes genotyping (e.g., 42 with *GBA*

- 376 mutations), medical record data, as well as repeat clinical score and survey
- measurements. Within HBS, year of diagnosis (but not day and month) were recorded. Thus, all
 analyses are done at the year of diagnosis level.
- 380 Fox Insight

Fox Insight is a web questionnaire-based, longitudinal study including both people having and not having Parkinson's disease (see publication for full description)⁴³. At the time of study, the Fox Insight database included 36,660 people with Parkinson's disease. The questionnaire covers the patient's medical and family histories, potential environmental exposures, as well as ongoing functional status. Additionally, genetic testing has been performed on a subset of the population.

387

388 Mass General Brigham (MGB) Electronic Medical Record

The MGB EMR (previously known as Partner's Health Care) includes > 6.8 million total
 active records from 1990 to 2020. Available data include encounters, diagnoses, medications,
 procedures, observations, and labs. The MGB EMR also includes a biobank with >36,000
 patients who have been genotyped with Illumina Multi-Ethnic Global Array (MEGA) microarray
 chip.

- The full EMR includes 22,949 patients with at least two diagnoses of PD as in Yuan et al.³⁰ (ICD9: 332, 332.0, ICD10: G20). To identify new onset PD, we required a two-year quiescence period (730 days) where a patient had encounters with the health system prior to having an initial diagnosis of PD and consider the time from initial (Supplemental Figure 1). There were 13,257 with encounters at least two years prior to their initial PD diagnosis. Full criteria for initial PD diagnosis are in the Study Design and Statistical Analysis section under *Initial Parkinson's Disease Diagnosis*.
- 401

402 Optum® Integrated Claims-EHR Data

403 Optum-provided description (quoted directly)⁴⁴: "Optum's Integrated Claims-Clinical 404 dataset combines adjudicated claims data with Optum's Electronic Health Record data. Optum's

405 longitudinal clinical and claims repository from Optum Analytics is derived from more than 50

406 healthcare provider organizations in the United States, that include more than 700 Hospitals and

- 407 7000 Clinics: treating more than 102 million patients receiving care in the United States.
- 408 Optum's Integrated Claims-EHR dataset is statistically de-identified under the Expert
- 409 Determination method consistent with HIPAA and managed according to Optum® and customer
- 410 data use agreements. The Integrated dataset, which leverages a proprietary Optum algorithm that
- 411 uses both salting and cryptographic hashing, links both claims and clinical data for
- 412 approximately 24M matched individuals. The Integrated dataset includes historical, linked
- 413 administrative claim data from pharmacy claims, physician claims, and facility claims, with EHR
- 414 information, inclusive of medications prescribed and administered, lab results, vital signs, body 415 measurements, diagnoses, procedures, and information derived from clinical notes using Natural
- 415 measurements, diagnoses, procedures, and information derived from clinical notes using Natural416 Language Processing."
- We identified a total of 157,475 patients with at least two distinct PD diagnoses after at
 least 730 days between coverage beginning and an initial PD diagnosis. Available data for this
 cohort include encounters, diagnoses, medications procedures, observations, and labs. Full
 criteria for initial PD diagnosis are in the Study Design and Statistical Analysis section under
- 421 Initial Parkinson's Disease Diagnosis.
- 422

423 <u>Study Design and Statistical Analysis</u>

424 Natural Language Processing Extraction of Clinical Rating Scales

We evaluated PD progression in accordance with common clinical scales: Hoehn & Yahr (H&Y)⁴⁵, Mini–Mental State Examination (MMSE)⁴⁶, Montreal Cognitive Assessment (MoCA)⁴⁷, and the Unified Parkinson's Disease Rating Scale (UPDRS).⁴⁸ Scores were available as structured data within HBS but needed to be extracted at MGB using natural language processing. While each scale includes subjective assessments, they have undergone validation studies^{10,48–58} and are commonly used in the assessment of PD and/or general cognitive progression.

To extract scores, we used the Flan-PaLM instruction-finetuned model²² (flan-t5-xxl) as the base for a few shot (n=10 with clinical scores, 10 without clinical scores) approach with exemplars. The prompt provided exemplars of a positive example and a negative example with the form (italics replaced with actual note content):

436 "Q: Answer the following question with a value between 1 and 5 or NA. What is the Hoehn &

437 Yahr score for the patient in the following note? Note: *Note Content* A: *3* Q: Answer the

438 following question with a value between 1 and 5 or NA. What is the Hoehn & Yahr score for the

- 439 patient in the following note? Note: *Note Content* A:"
- 440

We provided 10 prompts with exemplars that had clinical rating values present and 10 prompts with exemplars that did not have clinical rating scales for each extraction. We then compared the outputs between the inferences and flagged any notes with less than 9 out of 10 matching outputs. To verify that the model was appropriately finding scores when they were present, we manually reviewed the extracted scores for:

446

Hoehn & Yahr: 200 notes where the reviewer identified a score, 200 notes where the
model identified a score, 200 notes where no score was found by the model and 200 notes
where we manually identified that no score was found. For the 800 notes, extraction
accuracy was 99.75%; 2 notes were incorrect. Both cases were appropriately flagged, as
multiple Hoehn & Yahr values were recorded, and across the 10 runs only 4/10 and 5/10
scores matched.

454 UPDRS: 100 notes where the reviewer identified a score, 100 notes where the model 455 identified a score, 100 notes where no score was found by the model and 100 notes where 456 we manually identified that no score was found. For the 400 notes, model accuracy was 457 98%.

- MMSE: 100 notes where the reviewer identified a score, 100 notes where the model
 identified a score, 100 notes where no score was found by the model and 100 notes where
 we manually identified that no score was found. For the 400 notes model accuracy was
 99.50%
- 463

453

458

Across all 3 scores, no extraction with 9 or more matching outputs was incorrect in the randomly sampled evaluation sets. We therefore focused on reviewing all notes not included in our manual review pool that had inconsistent outputs across exemplar runs. This included 133 H&Y, 41 UPDRS, and 37 MMSE notes. The majority prediction (but less than 9) was correct for 94/133 H&Y notes, 36/41 UPDRS notes and 29/37 MMSE notes. We manually corrected the notes that did not meet our threshold with the human annotated value.

470

471 Definitions of Health Care Utilization and Clinical Events

472 Other definitions used to describe healthcare utilization and clinical events are provided in full in
473 Supplemental Tables 1-3 and described here.

474

475 Initial Parkinson's Disease Diagnosis

476 The initial Parkinson's disease diagnosis date is explicitly stated in both of the research 477 data cohorts (HBS, Fox Insight). Within the RWD, we required a 730-day quiescence period to 478 enrich for newly diagnosed PD (Supplemental Figure 1). Within Optum, this quiescence period 479 was defined by taking the first observed PD diagnosis (Defined in Supplemental Table 2) and 480 checking to see whether the subject had continuous coverage for the 730 days prior. To be 481 included within MGB, an individual needed to have at least one encounter 730 or more days 482 prior. In both RWD sources, subjects were then excluded if they did not have an additional PD 483 diagnosis at least 30 days after the initial PD diagnosis in an attempt to filter out codes used for 484 referral or diagnostic purposes.

- Within the RWD, subjects diagnosed with conditions that commonly result in clinical
 parkinsonism symptoms during the two-year quiescence period were excluded.³⁰ This included
 those with encephalitis, Alzheimer's disease, or other cognitive conditions mimicking idiopathic
 PD. Additionally those with conditions such as schizophrenia, Parkinson's-related disorders,
- 489 metabolic neurogenic anomalies (e.g., Wilson's Disease), or other degenerative ailments
- 490 resulting in clinical parkinsonism symptoms (e.g., Multiple system atrophy, Progressive
- 491 supranuclear palsy) were also excluded. The codes corresponding to these conditions are detailed
- 492 in Supplementary Table 2 and derived from Yuan et al.³⁰

This exclusion was not performed within HBS as subjects were screened by study personnel and it was not possible to perform within Fox Insights.

- 495
- 496 *Cognitive Decline*

497 Cognitive decline was defined as any diagnosis of mild cognitive impairment (ICD9: 498 331.83, ICD10: G31.84) a prescription for a medication typically used to treat cognitive 499 impairment during an encounter with a PD diagnosis (Aricept, Exelon, Namenda, Galantamine using national drug codes derived with RxNorm^{59,60}), or a referral for a neurology specialist for 500 cognitive decline. For HBS, an MMSE score with the cut-off of ≤ 25 was defined as an indicator 501 502 of significant global cognitive impairment as recommended by the International Parkinson and 503 Movement Disorders Society (MDS) Task Force. The RWD definition was developed in 504 conjunction with clinicians (led by CRS) and trial statisticians (JP, CC) to correlate as closely as 505 possible to the definition using MMSE with data available in RWD. To validate this metric, we 506 employed the Phi coefficient (\Box) , to quantify the degree of association between two binary 507 variables (matching cognitive decline definition, and MMSE threshold). We compared this 508 coefficient for 200 patients across 912 visits where both the RWD-cognitive decline definition 509 was available and a MMSE score is available. We obtained a \Box value of 0.848, suggesting a 510 strong correlation between the two definitions.

511

512 PD Therapeutics & Levodopa

513 Within Fox Insights and HBS the timing of PD therapeutic is explicitly asked of the 514 participant or entered by study staff respectively. Within HBS Levodopa initiation is explicitly 515 asked, but within Fox Insights it is not. Therefore, Fox Insights was not included in the analyses 516 for levodopa initiation.

517

522

523

524

For the RWD (Optum, MGB), PD therapeutic initiation (Supplemental Table 1) and levodopa
initiation was considered to be first date of a sequence prescription fills meeting all of the
following criteria:

- 521 a. Initial fill of a therapeutic listed in linked to an encounter with a PD diagnosis.
 - b. > 90 total days of pills.
 - c. 2+ fills occurring over a period of > 90 days but within 180 days from the first fill of the sequence.

525 These criteria aim to a.) ensure that the prescription is for PD, b.) the patient is not 526 receiving the medication as part of an evaluation or receiving a single 90-day fill, and c.) identify 527 the true starting point of treatment as opposed to evaluation.

- 528
- 529 Clinical Events Depression & Falls and Fractures

Adverse clinical events were represented by operational criteria for health care utilization and are defined in Supplemental Table 3. These criteria were developed by the Health Value & Economics team within Sanofi.⁶¹ Patients were required to have at least one code for the specified event as either the primary or admitting code for a visit which included an inpatient stay or treatment (procedures or medications). Patients were excluded from this analysis if they experienced diagnoses for the clinical event in question during the quiescence period.

536

537 Statistical Analyses

538 Statistical Tests and Survival Analyses

Quantitative population attributes (e.g., age of diagnosis) were first plotted using
Quantile-Quantile Plots followed by a Shapiro-Wilk test for normality. After determining
normality, Levene's test was used to assess whether variances were equal. In the case of age and
follow-up time, the variances were not equal and therefore a Welch's t-test was performed to
determine whether there were significant differences between the populations.

544 For Clinical rating scores (MMSE), after determining that the values were not normally 545 distributed, a Mann-Whitney U test was employed to compare scores between HBS and the 546 extracted scores from MGB.

547 Survival analyses against clinical events were conducted using the Kaplan-Meier method 548 to estimate the time-to-event distributions. These analyses were performed using the 'lifelines' 549 python package.⁶² For each patient, the time to clinical event (or last observed encounter) was 550 recorded along with an binary indicator denoting whether the event was observed or censored. 551 The resulting Kaplan-Meier survival curves visualize the time-to-event distributions, and we 552 used a log-rank test to compare these distributions between different groups.

553 Finally, to ascertain an average progression of UPDRS, MMSE, and H&Y we fit a linear 554 regression model accounting for the irregularity of sampling intervals. To do this we included the 555 age at diagnosis, time since diagnosis, sex, and number of years of education (within HBS only) 556 as covariates and fit a model to the appropriate clinical rating scale. Residual plots were 557 examined to verify the homoscedasticity and linearity assumptions. The normality of residuals 558 was assessed using quantile-quantile (QQ) plots and the Shapiro-Wilk test. Multicollinearity 559 among predictors was evaluated using the variance inflation factor (VIF), ensuring all VIF values 560 were below 10.

562 Missing Data

561

563 Within the two research databases, there was minimal missing data due to the overlap of 564 their study designs and the analyses in this work. Within HBS, data are entered by study 565 personnel who are instructed to complete all of fields used in this study. All participants had an 566 age at study visit, age at diagnosis, gender, race, and ethnicity at each study visit. Across all 567 study visits, H&Y was recorded in all visits and MMSE was recorded in all but 8 visits (99.8%). 568 Visits without a MMSE value were excluded from analyses. Within Fox Insights, participants 569 answer questions in panels in order as they sign up. Participants were excluded if they did not 570 complete the initial set of questions required for this study. In the RWD, data are only available 571 through normal clinical care when patients have interactions with the healthcare system. Study 572 inclusion criteria were selected to maximize the likelihood that patient encounters would be 573 captured. To this end, patients were required to either have coverage (Optum) or have prior visits 574 (MGB) at least two years prior to their initial PD diagnosis. This was put in place to both filter 575 for new diagnoses of PD as well as to limit patients who were referred after an initial diagnosis.

576 Additionally, many visits do not include a full PD-specific work up and/or do not record 577 PD clinical rating scores. Less than 10% of patients had an initial H&Y score included in their note (1,071 of 13,257 patients, 8.08%). Similar to prior work⁶³, we trained simple machine 578 579 learning classifiers to predict whether a score would be present based on a patient's age, sex, age 580 at initial diagnosis, binary presence of comorbidities (rolled up to PheWAS codes),⁶⁴ distance 581 from the clinic, which clinic, and physician specialty. Outside of physician specialty, no feature 582 was determined to be significant and even with physician specialty, performance was only 583 marginally better than random (AUC: 0.56). Due to the relative rarity, lack of a clear discernable 584 pattern of presence, and the fact that it could not be determined that missingness was dependent

- 585 on outcome, we elected not to perform imputation and instead to include clinical rating scores
- 586 only where they were available in the notes. This approach comes with an important caveat, the
- 587 patients with scores may not be representative of the entire cohort. The reasons for missing
- 588 scores may not be observed, whether related to disease severity, accessibility to care, or other
- 589 clinical factors, could systematically differ between those with and without scores. This study
- 590 aims to mitigate these challenges by using multiple datasets and presents a comparison between
- 591 these datasets to better understand these biases.
- 592 593

594 Standard Protocol Approvals, Registrations, and Patient Consents

- 595 This study was approved by the Mass General Brigham Institutional Review Board 596 (#2017P002452). This study received only de-identified, retrospective data from research
- 597 datasets (HBS and Fox). Research dataset participants are consented for study and publication as
- 598 part of the recruitment process. Real world datasets (MGB and Optum) are retrospective de-
- 599 identified data and therefore individual consent is not required for publication.
- 600

601 Data Availability

- 602 Authors had primary access to all data sources used in this study (BKB). All data used in this 603 study are secondary use and therefore the authors must direct those interested in using any data
- 604 involved to their source:
- 605

606	1.	Harvard Biomarkers set is accessible through Accelerating Medicines Partnership
607		program for Parkinson's disease <u>https://amp-pd.org/unified-cohorts/hbs</u> and through
608		https://www.bwhparkinsoncenter.org/biobank/
609	2.	Mass General Brigham EMR; https://rc.partners.org/about/who-we-are-risc/research

- 2. Mass General Brigham EMR; https://rc.partners.org/about/who-we-are-risc/researchpatient-data-registry
- 3. Optum® Integrated Claims-EHR Data⁴⁴ 611 (https://www.optum.com/content/dam/optum3/optum/en/resources/fact-612 sheets/Integrated-Data-product-sheet.pdf), 613 614
 - 4. Fox Insight⁴³ https://foxinsight.michaelifox.org/
- 615

610

616

617 Author Contributions

	Conception or design of the work	Acquisition of data	Analysis of Data	Interpretation of Data	Manuscript draft	Revision
Brett K. Beaulieu- Jones ¹	x	x (pre- processing)	X	x	x	X
Francesca Frau	X		X	X		Х
Sylvie Bozzi	X		Х	X	Х	Х
Karen J. Chandross	X			X	X	Х
M Judith Peterschmitt			Х	X	X	Х
Caroline Cohen			x	Х	X	x
Catherine Coulovrat			Х	Х	X	Х
Dinesh Kumar				Х		x
Mark Kruger		X		Х	Х	х
Scott L. Lipnick	X	X			X	X
Lane Fitzsimmons					Х	Х
Isaac S. Kohane	X			Х	X	Х
Clemens R. Scherzer	X	X		х	X	х

618

619 Acknowledgements

- 620 This work was funded in part by the Sanofi iDEA Awards Initiative (BKB) as well the National
- 621 Institute of Neurological Disorders and Stroke grant number (K99NS114850, R00NS114850).
- 622 CRS's work is supported in part by NIH grants NINDS/NIA R01NS115144, U01NS095736,
- 623 U01NS100603, the U.S. Department of Defense, and the American Parkinson Disease
- 624 Association Center for Advanced Parkinson Research. The Fox Insight Study (FI) is funded by
- The Michael J. Fox Foundation for Parkinson's Research. This research was funded in part by
- Aligning Science Across Parkinson's [ASAP-000301] through the Michael J. Fox Foundation for
- 627 Parkinson's Research (MJFF). We would like to thank the Parkinson's community for
- 628 participating in this study to make this research possible. We would like to acknowledge Cliona
- 629 Molony and Sanofi Digital, for facilitating data access through the Sanofi Darwin platform to
- 630 support this project. We would also like to thank all of the participants and organizers of the
- Harvard Biomarker Study as well as the organizers of the Research Patient Data Registry at
- Mass General Brigham. For the purpose of open access, the author has applied a CC BY public
- 633 copyright license to all Author Accepted Manuscripts arising from this submission.
- 634

635 **Competing Interest**

- FF, SB, KJC, MJP, CC, DK, CC are employees of Sanofi and may hold shares and/or stock
 options in the company. All authors declare no other competing financial or non-financial
 interests.
- 638 in 639

640 **References**

- Kalia, L. V., Kalia, S. K. & Lang, A. E. Disease-modifying strategies for Parkinson's disease. *Mov. Disord.* 30, 1442–1450 (2015).
- 643 2. Dawson, V. L. & Dawson, T. M. Promising disease-modifying therapies for Parkinson's disease. *Sci. Transl. Med.* 11, (2019).
- 645 3. Zheng, B. *et al.* PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. *Sci. Transl. Med.* 2, 52ra73 (2010).
- 647 4. Iwaki, H. *et al.* Genomewide association study of Parkinson's disease clinical biomarkers in
 648 12 longitudinal patients' cohorts. *Mov. Disord.* 34, 1839–1850 (2019).
- 649 5. Blauwendraat, C. *et al.* Parkinson's disease age at onset genome-wide association study:
 650 Defining heritability, genetic loci, and α-synuclein mechanisms. *Mov. Disord.* 34, 866–875
 651 (2019).
- 6. van Rooden, S. M. *et al.* The identification of Parkinson's disease subtypes using cluster
 analysis: A systematic review. *Mov. Disord.* 25, 969–978 (2010).
- 654 7. Thenganatt, M. A. & Jankovic, J. Parkinson Disease Subtypes. *JAMA Neurol.* 71, 499
 655 (2014).
- 8. Jankovic, J. *et al.* Variable expression of Parkinson's disease: A base-line analysis of the
 DAT ATOP cohort. *Neurology* 40, 1529–1529 (1990).
- 658 9. Liu, G. *et al.* Specifically neuropathic Gaucher's mutations accelerate cognitive decline in
 659 Parkinson's. *Ann. Neurol.* 80, 674–685 (2016).
- Liu, G. *et al.* Prediction of cognition in Parkinson's disease with a clinical–genetic score: a
 longitudinal analysis of nine cohorts. *Lancet Neurol.* 16, 620–629 (2017).
- Liu, G. *et al.* Genome-wide survival study identifies a novel synaptic locus and polygenic
 score for cognitive progression in Parkinson's disease. *Nat. Genet.* 53, 787–793 (2021).

- 12. Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications.
 Nat. Genet. 47, 856–860 (2015).
- Liu, G. *et al.* Mitochondrial haplogroups and cognitive progression in Parkinson's disease. *Brain* 146, 42–49 (2023).
- 668 14. Mittal, S. *et al.* β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of 669 Parkinson's disease. *Science* **357**, 891–898 (2017).
- 670 15. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative
 671 (PPMI). *Prog. Neurobiol.* 95, 629–635 (2011).
- 672 16. Beaulieu □ Jones, B. K. *et al.* Examining the Use of Real □ World Evidence in the
 673 Regulatory Process. *Clin. Pharmacol. Ther.* **318**, 703 (2019).
- Karlson, E. W., Boutin, N. T., Hoffnagle, A. G. & Allen, N. L. Building the Partners
 HealthCare Biobank at Partners Personalized Medicine: Informed Consent, Return of
 Research Results, Recruitment Lessons and Operational Considerations. *J Pers Med* 6,
 (2016).
- Wallace, P. J., Shah, N. D., Dennen, T., Bleicher, P. A. & Crown, W. H. Optum Labs:
 building a novel node in the learning health care system. *Health Aff.* 33, 1187–1194 (2014).
- Agrawal, M., Hegselmann, S., Lang, H., Kim, Y. & Sontag, D. Large language models are
 few-shot clinical information extractors. in *Proceedings of the 2022 Conference on Empirical Methods in Natural Language Processing* 1998–2022 (Association for
 Computational Linguistics, 2022).
- 684 20. Singhal, K. *et al.* Large Language Models Encode Clinical Knowledge. *arXiv* [*cs.CL*]
 685 (2022).
- 686 21. Chowdhery, A. *et al.* PaLM: Scaling Language Modeling with Pathways. *arXiv* [*cs.CL*]
 687 (2022).
- 688 22. Chung, H. W. et al. Scaling Instruction-Finetuned Language Models. arXiv [cs.LG] (2022).
- 689 23. Brown, T. B. et al. Language Models are Few-Shot Learners. arXiv [cs.CL] (2020).
- 690 24. Huang, Y., Yuan, W., Kohane, I. S. & Beaulieu-Jones, B. K. Illustrating potential effects of
 691 alternate control populations on real-world evidence-based statistical analyses. *JAMIA Open*692 4, ooab045 (2021).
- 693 25. Holden, S. K., Finseth, T., Sillau, S. H. & Berman, B. D. Progression of MDS-UPDRS
 694 Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression
 695 Markers Initiative Cohort. *Mov Disord Clin Pract* 5, 47–53 (2018).
- 696 26. Spindler, M. A. & Tarsy, D. Initial pharmacologic treatment of Parkinson disease. in
 697 UpToDate (2019).
- Talman, L. Quality of Life for Patients With Parkinson Disease. *Neurology* 98, e2293–
 e2295 (2022).
- Bock, M. A., Brown, E. G., Zhang, L. & Tanner, C. Association of Motor and Nonmotor
 Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With
 Parkinson Disease. *Neurology* 98, e2194–e2203 (2022).
- 29. Ludmir, E. B. *et al.* Factors Associated With Age Disparities Among Cancer Clinical Trial
 Participants. *JAMA Oncol* 5, 1769–1773 (2019).
- Yuan, W. *et al.* Accelerating diagnosis of Parkinson's disease through risk prediction. *BMC Neurol.* 21, 201 (2021).
- Fereshtehnejad, S.-M. *et al.* New Clinical Subtypes of Parkinson Disease and Their
 Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.
 JAMA Neurol. 72, 863–873 (2015).

- Jankovic, J. & Kapadia, A. S. Functional decline in Parkinson disease. *Arch. Neurol.* 58, 1611–1615 (2001).
- 33. Burn, D. J. *et al.* Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. *J. Neurol. Neurosurg. Psychiatry*714 77, 585–589 (2006).
- Alves, G., Larsen, J. P., Emre, M., Wentzel-Larsen, T. & Aarsland, D. Changes in motor
 subtype and risk for incident dementia in Parkinson's disease. *Mov. Disord.* 21, 1123–1130
 (2006).
- 718 35. Kotagal, V. Is PIGD a legitimate motor subtype in Parkinson disease? Ann Clin Transl
 719 Neurol 3, 473–477 (2016).
- 36. Braunholtz, D. A., Edwards, S. J. L. & Lilford, R. J. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect." *J. Clin. Epidemiol.* 54, 217–224 (2001).
- 37. McCarney, R. *et al.* The Hawthorne Effect: a randomised, controlled trial. *BMC Med. Res. Methodol.* 7, 30 (2007).
- 38. Vivacqua, G. *et al.* Salivary α-Synuclein RT-QuIC Correlates with Disease Severity in de
 novo Parkinson's Disease. *Mov. Disord.* 38, 153–155 (2023).
- 39. Ding, H. *et al.* Unrecognized vitamin D3 deficiency is common in Parkinson disease:
 Harvard Biomarker Study. *Neurology* 81, 1531–1537 (2013).
- 40. Huh, Y. E. *et al.* β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. *Neurology* **95**, e685–e696 (2020).
- 41. Locascio, J. J. *et al.* Association between α-synuclein blood transcripts and early,
 neuroimaging-supported Parkinson's disease. *Brain* 138, 2659–2671 (2015).
- 42. al., A. O. et. The Harvard Biomarker Study: Biomarkers for Parkinson's. *In prep*.
- 43. Smolensky, L. *et al.* Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease. *Sci Data* 7, 67 (2020).
- 735 44. Optum. Optum's de-identified Integrated Claims-Clinical dataset (2007-2019). (2020).
- 45. Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression, and mortality. 1967. *Neurology* 50, 318 and 16 pages following (1998).
- Folstein, M. F., Robins, L. N. & Helzer, J. E. The Mini-Mental State Examination. *Arch. Gen. Psychiatry* 40, 812 (1983).
- 740 47. Nasreddine, Z. S. *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool
 741 for mild cognitive impairment. *J. Am. Geriatr. Soc.* 53, 695–699 (2005).
- 48. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The
 Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. *Mov. Disord.* 18, 738–750 (2003).
- 49. Goetz, C. G. *et al.* Movement Disorder Society Task Force report on the Hoehn and Yahr
 staging scale: status and recommendations the Movement Disorder Society Task Force on
 rating scales for Parkinson's disease. *Mov. Disord.* 19, 1020–1028 (2004).
- 50. Gallagher, D. A., Goetz, C. G., Stebbins, G., Lees, A. J. & Schrag, A. Validation of the
 MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. *Mov. Disord.* 27, 79–
 83 (2012).
- 51. Müller, J. *et al.* Progression of Hoehn and Yahr stages in Parkinsonian disorders: a
 clinicopathologic study. *Neurology* 55, 888–891 (2000).
- 52. Siciliano, M. *et al.* Cognitive impairment is associated with Hoehn and Yahr stages in early,
 de novo Parkinson disease patients. *Parkinsonism Relat. Disord.* 41, 86–91 (2017).

- 53. Martinez-Martin, P. *et al.* Expanded and independent validation of the Movement Disorder
 Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). *J. Neurol.* 260, 228–236
 (2013).
- 54. Goetz, C. G., Stebbins, G. T. & Tilley, B. C. Calibration of unified Parkinson's disease
 rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale
 scores. *Mov. Disord.* 27, 1239–1242 (2012).
- 55. Skorvanek, M. *et al.* Differences in MDS-UPDRS scores based on Hoehn and Yahr stage
 and disease duration. *Mov. Disord. Clin. Pract.* 4, 536–544 (2017).
- 56. Hoops, S. *et al.* Validity of the MoCA and MMSE in the detection of MCI and dementia in
 Parkinson disease. *Neurology* 73, 1738–1745 (2009).
- Fountoulakis, K. N., Tsolaki, M., Chantzi, H. & Kazis, A. Mini Mental State Examination
 (MMSE): A validation study in Greece. *Am. J. Alzheimers. Dis. Other Demen.* 15, 342–345
 (2000).
- 58. Beaman, S. R. de *et al.* Validation of a modified version of the Mini-Mental State
 Examination (MMSE) in Spanish. *Neuropsychol. Dev. Cogn. B Aging Neuropsychol. Cogn.*11, 1–11 (2004).
- 59. Liu, S., Ma, W., Moore, R., Ganesan, V. & Nelson, S. RxNorm: prescription for electronic drug information exchange. *IT Prof.* 7, 17–23 (2005).
- Nelson, S. J., Zeng, K., Kilbourne, J., Powell, T. & Moore, R. Normalized names for clinical drugs: RxNorm at 6 years. *J. Am. Med. Inform. Assoc.* 18, 441–448 (2011).
- 61. Giladi, N. *et al.* Safety and efficacy of venglustat in GBA1-associated Parkinson's disease:
 an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 22, 661–671 (2023).
- 778 62. Davidson-Pilon, C. et al. Lifelines. (2018). doi:10.5281/ZENODO.1210821.
- Beaulieu-Jones, B. K. *et al.* Characterizing and Managing Missing Structured Data in
 Electronic Health Records: Data Analysis. *JMIR Med Inform* 6, e11 (2018).
- 64. Denny, J. C. *et al.* PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics* 26, 1205–1210 (2010).